MA-IBASIS
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and KPN, the Netherlands’ leading telecom company, announced today that they have renewed their outsourcing agreement for Voice and Mobile services for three years.
Since its sale by KPN in 2019, iBASIS and its global team have been dedicated to bringing KPN best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. Cost stability, capacity planning, and fraud prevention have been instrumental in sustaining the Dutch operator’s traffic growth.
The renewal underscores the success of iBASIS’ model and long-term relationship with managing KPN’s international traffic growth, including IPX cooperation to handle the surge in mobile data traffic. iBASIS reports an 80% year-on-year growth in Diameter traffic, which has enabled KPN to deliver reliable, high-speed data roaming services to its subscribers. The network scalability has been critical in meeting the explosive 4G and 5G mobile data roaming demand, including traffic peaks resulting from the rise of M2M connections.
“iBASIS has been a trusted partner of KPN for the past six years, managing our international voice and mobile services. Leveraging their consolidation model and economies of scale, we outsource nearly 100% of our voice business to iBASIS. Their partner program is focused on delivering quality, transparency, and actionable business insights,” said Michel van Wissen, Executive Vice President, Wholesale, KPN. “We have extended our partnership for another three years. Our excitement is based on proven past successes and on the innovation iBASIS continues to demonstrate in meeting the challenges providers face now and in the future.”
Outsourcing international voice and mobile services also enables KPN to focus on its retail and wholesale business as well as technology initiatives associated with developing these segments.
“We enjoy a strong and mutually beneficial relationship with KPN on voice and mobile services,” added Edwin van Ierland, CEO, iBASIS Voice & Mobile Data. “We are more than a supplier; we are a growth partner. As such, we are very motivated to help KPN leverage our global platform and capabilities to the fullest. The renewal illustrates our excellent relationship, centered on transparency and open communication. It again demonstrates that the outsourcing model chosen by KPN is highly effective.”
“KPN’s three-year renewal is the recognition of iBASIS/Tofane past and future excellence thanks to our unique mix of scale, innovation, and entrepreneurship,” said Alexandre Pébereau, Group CEO and Founder, Tofane Global. “Our performance is recognized again by ROCCO as a top Tier One International Voice Carrier,* Telegeography Fourth Voice Carrier,** and First Independent Carrier.”
In 2023, iBASIS was ranked by 227 MNOs as the top Tier One International Voice Carrier for Performance, Performance+, Leadership, General Rating, and Overall Rating, with the highest results for Global Presence, Local Expertise, R&D Investment, Trusted, Innovative, Dynamic, and Enabler.*
*ROCCO Research: International Voice Carrier Market Impact Report 2023
**Telegeography International Voice Report 2024
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT.
About KPN
KPN has been the leading provider of telecommunications and IT services in the Netherlands for almost 140 years. Everyone in the Netherlands uses the KPN network on a daily basis, either directly or indirectly, from the high-speed fibre networks in the ground to payment card machines in shops, or the matrix boards above the motorways. Via the network of the Netherlands, in which KPN continuously invests by rolling out fibre and the introduction of new technologies such as the 5G mobile network, KPN serves consumers and business customers with services for telephony, data, television, internet-of-things, cloud, workplaces and security. KPN has an open network on which other providers also offer services. More information is available at www.kpn.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220905856/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom